CClinicalTrials.gg
Not yet recruitingNCT07191366EXPRESSMOM2Updated Sep 24, 2025

Antenatal Breastmilk Expression in Pregnant Women at High Risk of Preterm Birth

An interventional study of Handstimulation of breast in Preterm Birth, PPROM and Preeclampsia, sponsored by Odense University Hospital. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

In this randomized controlled study, the investigators aim to examine if antenatal breastmilk expression (aBME) from week 28 in high-risk pregnancies is a safe and effective method to ensure early access to mother's own milk.

In addition, this study will analyze and compare colostrum from pregnancy with colostrum after birth, investigates women's confidence in breastfeeding and breastfeeding establishment as well as measures oxytocin levels during aBME and active labour with no aBME.

Read the detailed description

In this study 250 pregnant women at high risk of preterm birth (Diagnosed with either preeclampsia or PPROM or previously delivered preterm before week 34) from the Region of Southern Denmark, will be randomized into an intervention or a control group.

Women in the intervention group will be instructed to perform antenatal breastmilk expression twice daily for 5 minutes on each breast from inclusion at week 28-34 until birth. Women will be advised to collect any expressed milk and bring to the delivery ward for use after birth.

A total of 40 minutes of Cardio Toco Graphy (CTG) will be performed before, during and after they perform aBME for the first time, to detect any uterine contractions or foetal compromise due to stimulation. If the CTG is normal the women can begin aBME at home.

Furthermore, the women will be asked to answer a questionnaire about breastfeeding self-efficacy at inclusion and 2 weeks after aBME starts. Small amounts of the colostrum expressed before and after birth will be analysed for specific proteins, bioactive components and amount and types of Lactobacillus strains.

Women admitted to Odense University Hospital will be asked for a single blood sample to measure oxytocin. Samples will be drawn during the first aBME and at birth.

8 women/parents will be asked to participate in an observational study. Observations will follow breastfeeding practices within the first two days and afterward, weekly, during the first three weeks postpartum.

A subgroup of 12 mothers with a pre-pregnancy BMI above ≥30kg/m2 who give birth at term will be asked to participate in an in-depth face-to-face interview. The interviews will be conducted in the participant´s home 4-6 weeks postpartum to explore experiences with breastfeeding establishment after performing aBME.

The women in the control group will follow standard care and be asked to answer a questionnaire about breastfeeding self-efficacy at inclusion. Furthermore, women admitted to Odense University Hospital will be asked for a single blood sample to measure oxytocin. The sample will be drawn during randomization and at birth.

After birth, 8 women/parents will be asked to participate in an observational study. Observations will follow breastfeeding practices within the first two days and, afterward, weekly during the first three weeks.

The women from both groups will be followed until 6 months postpartum to monitor outcomes related to breastfeeding, nutrition, growth, and infections. Until four weeks after the infant's corrected age, all women in both groups receive weekly push messages through the smartphone application, including questions on feeding postpartum. If admitted, the feeding will be registered at the hospital through electronic health records. The following five months, all women in both groups will receive monthly push messages through the smartphone application, including post-partum feeding questions.

Furthermore, all women will be asked to answer a questionnaire related to breastfeeding self-efficacy 3 weeks after birth.

02

Conditions studied

  • Preterm Birth
  • PPROM
  • Preeclampsia
  • Previous Preterm Birth

Keywords

  • Antenatal breastmilk expression
  • ABME
  • Preterm birth
  • PPROM
  • Preeclampsia
  • Previous preterm birth
  • Colostrum
  • Colostrum analysis
  • Safety
  • self-efficacy
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Pregnant women with a GA between 28 weeks and 0 days and 34 weeks and 0 days who are either diagnosed with preeclampsia or PPROM or have previously given birth before 34 weeks of gestation
  • Resident in the Region of Southern Denmark
  • Women speaking and understanding Danish or English
  • Planning to breastfeed their infants

Exclusion criteria

Exclusion Criteria:

  • HELLP or severe preeclampsia indicating expected induction of labour/caesarean section within a few days (According to national guidelines)
  • Chorioamnionitis indicating induction of labour/caesarean section within a few days
  • Women with a vaginal cerclage and PPROM
  • Women taking medications contraindicating breastfeeding
  • Women with prior breast reductive surgery or mastectomy
  • Below 18 years of age
  • Contractions to a certain extend expecting delivery within a few days
  • Included in other trials, where breastfeeding is among outcomes
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Handstimulation of the breasts

    Antenatal breastmilk expression and colostrum collection

    Procedure: Handstimulation of breast

  • No intervention
    Control

Interventions

  • ProcedureHandstimulation of breast

    Hand stimulation of the breast

    Also known as: aBME, Breastmilk expression

05

What researchers measure

Primary outcomes

  1. Number of days from randomization to birth

    To investigate the safety of antenatal breastmilk expression in pregnant women at high risk of preterm birth included from week 28 to 34 of pregnancy

    Time frame: From date of randomization at 28 weeks to 34 weeks of pregnancy until the date of birth. Up to 100 days.

Secondary outcomes

  1. Amount of available mothers own milk at birth

    Availability of mothers own milk for the newborn infant after antenatal breastmilk expression in pregnancy

    Time frame: At birth

  2. Oxytocin levels

    To compare oxytocin levels from performing antenatal breastmilk expression or not

    Time frame: At two time points. Baseline at randomization for the control group and during the first time with handstimulation of the breast in the intervention group. Second time point in both groups: During active labour.

  3. Colostrum analysis

    To characterize macronutrients, microbial and bioactive composition in colostrum expressed before and after birth

    Time frame: From pregnancy to one week after birth

  4. Postnatal outcomes in infants (Height in cm, weight in kg, hospital treatments, admittance to NICU, duration of admittance, occurence of infections, nutrition, early feeding, hypoglyceamia)

    To compare feeding intolerance, risk of infection and NEC in infants fed only mothers own milk compared to mothers own milk and/or donor human milk

    Time frame: From date of birth to six months post partum.

  5. Maternal breastfeeding self-efficacy changes in questionnaires.

    To investigate if antenatal breastmilk expression affects maternal breastfeeding self-efficacy.

    Time frame: From date of randomization to 3 weeks post-partum

  6. Breastfeeding establishment after antental breastmilk expression in obese women

    To examine experiences with breastfeeding establishment in women with obesity performing antenatal breastmilk expression or not

    Time frame: At 4-6 weeks post-partum

  7. Observations regarding number of tools/strategies from antenatal breastmilk expression

    Number of tools and strategies in breastfeeding establishment after performing antenatal breastmilk expression in pregnancy

    Time frame: Within the first 3 weeks of post-partum

  8. Number of women exclusively breastfeeding.

    To investigate if antenatal breastmilk expression affects rates of exclusive breastfeeding

    Time frame: From date of birth to 3 weeks post partum.

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07191366
Lead sponsor
Odense University Hospital
Collaborators
Aabenraa Hospital, Esbjerg Hospital - University Hospital of Southern Denmark, Kolding Sygehus, University of Aarhus
Responsible party
Sponsor
First posted
Sep 24, 2025
Start date
Sep 2026 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jul 2029 (estimated)
Last update
Sep 24, 2025

Study contacts

Gitte Zachariassen, Professor, MD, ph.d.
Contact
gitte.zachariassen@rsyd.dk
+4522402549
Leonora S Borum, MD
Contact
leonora.semine.borum@rsyd.dk
+4550541738
Gitte Zachariassen, MD, phd
study chair · The Hans Christian Andersen Children's Hospital, Odense University Hospital
Christina A Vinter, MD, phd
study chair · The Department of Gynaecology and Obstetrics, Odense University Hospital
Leonora S Borum, MD
principal investigator · The Hans Christian Andersen Children's Hospital, Odense University Hospital
Sarah B Bentzen, Midwife
principal investigator · The Hans Christian Andersen Children's Hospital, Odense University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion